Welcome to our dedicated page for NEKTAR THERAPEUTICS SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics (NKTR) announced that it is entering a quiet period starting September 8, 2026, which will continue until the public announcement of data from the 24-week off-treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
The company states that this quiet period is consistent with its prior quiet periods for Phase 2b REZOLVE studies and planned data disclosures, and the information is furnished under Regulation FD rather than filed.
NEKTAR THERAPEUTICS (NKTR) reported that Chief R&D Officer Jonathan Zalevsky sold 186 shares of common stock on August 18, 2026 at a weighted-average price of $71.98 per share. The sale was made solely to cover required tax withholding upon RSU vesting and is not a discretionary trade. After this sale, he holds 9,570 shares of NKTR common stock directly.
NEKTAR THERAPEUTICS (NKTR) reported that President & CEO and director Howard W. Robin sold 418 shares of common stock on 2026-08-18 at a weighted average price of $71.98 per share, in trades executed between $71.78 and $72.49. According to the company’s disclosure, these shares were sold to cover required tax withholding obligations arising from the vesting of Robin’s RSUs and did not represent a discretionary trade. After this sale, Robin held 54,627 shares directly, and an additional 28 shares were reported as indirectly owned by his spouse.
NEKTAR THERAPEUTICS (NKTR) had a Form 144 notice filed in connection with planned sales of its common stock by officer Jonathan Zalevsky. The notice covers a proposed sale of 186 shares of NKTR common stock, with an aggregate market value of $13,387.96 as of August 18, 2026, to be sold on NASDAQ. The securities to be sold were acquired through restricted stock vesting on August 14, 2026, as compensation from the issuer. The filer also reports that the planned sale includes shares needed to cover a related tax obligation, and notes a prior sale of 199 shares for $13,035.36 on May 19, 2026.
NEKTAR THERAPEUTICS (NKTR) is named as the issuer in a notice that Howard Robin intends to sell common stock under Rule 144. The notice covers a planned sale of 418 shares of common stock held at Fidelity Brokerage Services LLC, with a stated market value of $30,086.93 as of August 18, 2026, on the NASDAQ market.
The shares to be sold arise from restricted stock vesting on August 14, 2026, identified as compensation from the issuer. The filing also lists prior sales of NKTR common stock by Howard Robin over the past three months, with the filer noting that the sale includes an amount to cover tax obligations from a vested equity award distribution.
Nektar Therapeutics is reported to have a significant shareholder group led by Two Seas Capital LP, its general partner Two Seas Capital GP LLC, and Sina Toussi. As of June 30, 2026, these reporting persons collectively beneficially owned 3,092,234 shares of Nektar Therapeutics common stock, representing 9.1% of the outstanding shares, based on 34,129,664 shares outstanding. The shares are held through Two Seas Global (Master) Fund LP and Two Seas Litigation Opportunities Fund LLC, with investment and voting discretion granted to Two Seas Capital. The reporting persons state they have sole voting and dispositive power over these shares and no shared voting or dispositive power.
Biotechnology Value Fund and related entities filed Amendment No. 2 to a Schedule 13G reporting their beneficial ownership in Nektar Therapeutics common stock. As of June 30, 2026, BVF, BVF2 and Biotechnology Value Trading Fund OS together beneficially owned 2,391,075 shares of Nektar common stock.
Based on 33,786,032 shares outstanding as of May 1, 2026, BVF beneficially owned about 3.7%, BVF2 2.8%, and Trading Fund OS less than 1% of the class. Through their roles as general partners and investment manager, BVF GP Holdings LLC, BVF Partners L.P., BVF Inc. and Mark N. Lampert may each be deemed to beneficially own approximately 7.1% of Nektar’s outstanding common stock, with all such beneficial ownership relationships and certain disclaimed interests described in detail.
Nektar Therapeutics reported a first-half 2026 net loss of $85.5 million, modestly improved from $92.5 million a year earlier, on $21.0 million of non-cash royalty revenue. Operating expenses were $102.4 million, driven mainly by increased research and development spending on rezpegaldesleukin and TNFR2 programs.
Liquidity strengthened significantly: cash and investments in marketable securities totaled $1.02 billion at June 30, 2026, up from $245.8 million at year-end, largely from equity offerings that raised $1.07 billion in net proceeds between July 2025 and April 2026. The company states it has sufficient capital to fund operations for at least 12 months.
Nektar remains a clinical-stage immunology company focused on rezpegaldesleukin in atopic dermatitis, alopecia areata and Type 1 diabetes, with Phase 3 ZENITH AD trials recently initiated and Phase 2b REZOLVE-AD and REZOLVE-AA trials ongoing. The business continues to incur substantial losses and expects significant ongoing R&D investment.
Nektar Therapeutics reported second quarter 2026 results, highlighting a strengthened balance sheet and continued investment in its immunology pipeline. Cash and investments in marketable securities were $1,023.4 million at June 30, 2026, up from $245.8 million at December 31, 2025, and management stated this supports a cash runway into the third quarter of 2028.
Revenue for the quarter was $10.1 million, slightly below $11.2 million a year earlier, all from non-cash royalty revenue related to sales of future royalties. Total operating costs and expenses rose to $52.5 million from $47.4 million, driven by higher research and development spending as Phase 3 activities for lead candidate rezpegaldesleukin ramped, while general and administrative costs declined.
Net loss was $40.6 million, or $1.23 per share, compared with a net loss of $41.6 million, or $2.95 per share, in the prior-year quarter. The company has initiated its first Phase 3 ZENITH AD trials in atopic dermatitis, plans a registrational Phase 3 in alopecia areata in early 2027, and is targeting an initial BLA submission for rezpegaldesleukin in 2029.
Vanguard Capital Management reports beneficial ownership of Nektar Therapeutics common stock. Vanguard and certain affiliated entities collectively hold 1,747,653 shares of Nektar common stock, representing 5.17% of the class as of June 30, 2026.
Within this position, Vanguard has sole voting power over 250,804 shares and sole dispositive power over 1,747,653 shares, with no shared voting or dispositive power reported. The holdings include securities in Vanguard funds and managed accounts over which Vanguard or its specified affiliates exercise voting and/or dispositive authority. No other single person’s interest in these securities exceeds 5% of the class.